Salvia Therapeutics

News

Salvia raises 26 million euros to finance migraine neurostim...

Salvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation therapy for chronic migraine.

News

Hengrui gets world-first okay for platelet drug hetrombopag

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks